– Sandwich, UK -- Levicept Ltd., an asset-centric biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces that it has commenced its Phase I trial of LEVI-04 in healthy volunteers and osteoarthritis patients…
– Data show clinically meaningful improvement in overall survival in a biomarker-defined patient population with late-stage metastatic colorectal cancer COPENHAGEN, Denmark - Symphogen, an advanced clinical-stage antibody company focused on oncology, today announced detailed results…
– Key Updates Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation. Top-line trial data are expected to be issued in a press release post-market close on Monday, September 25, 2017, followed by a conference…
– UTRECHT, THE NETHERLANDS – Gilde Healthcare, the European specialist investor, today announces it has sold its majority share in Viroclinics Biosciences (Viroclinics), the contract research organization (CRO), to Parcom Capital. Gilde Healthcare invested in 2013 out of its Gilde…
– ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2- negative breast cancer, to inform decisions on withholding chemotherapy ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for 1-3 lymph node positive…
– IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics announces that the 15th St. Gallen International Breast Cancer Guidelines recently published in Annals of Oncology1 have recommended the MammaPrint® 70-Gene Breast Cancer…
– Malta STAT-Dx EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain The EIB is providing STAT-Dx (STAT-Diagnostica & Innovation, S.L.), a Spanish company developing advanced molecular diagnostic systems to help combat…
– IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that Blue Shield of California has updated its Medical Policy 2.04.36 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis…
– Key Updates ProQR receives Fast Track designation by the U.S. Food and Drug Administration (FDA). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients with Leber's Congenital Amaurosis Type 10 (LCA 10). LCA 10 is one of the most prevalent…
– Recruitment of 301 patients in STOP-AKI adaptive Phase II trial marks largest ever therapeutic study in AKI Bunnik, The Netherlands — AM-Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (reCAP) for inflammatory diseases,…
– Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber's congenital amaurosis Type 10 (LCA 10) patients LCA 10 is one of the most prevalent forms…
– Funding Intended to Support FDA Approval and Early US Commercialization of Unicompartmental Load Absorber for Knee Osteoarthritis HAYWARD, California - Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA),…
– Bedford, Massachusetts — Otto Bock HealthCare GmbH, a global leader in prosthetics and orthotics, announced the acquisition of BionX Medical (BionX), a US-based portfolio company of Gilde Healthcare. BionX's flagship product is emPOWER, the world's only active prosthetic foot that…
– Utrecht, the Netherlands — Gilde Healthcare today announces its investment in Breath Therapeutics, a company developing advanced drug-aerosol therapeutics in pulmonary orphan indications. Gilde Healthcare participated in a €43.5 million Series A financing round together with Sofinnova…
– NDA to be submitted to the US FDA 1H 2017 Cambridge, UK – Acacia Pharma Group Ltd ("Acacia"), the supportive care company, announces positive results from its fourth and final pivotal Phase 3 study investigating its lead product BAREMSIS™ for the rescue treatment of patients who…
– Shock Absorber for the Knee Targets Patients Who Are Seeking Alternatives to Joint Replacement HAYWARD, Calif. – Moximed®, Inc. announced today that the first patient has been treated in an FDA-approved IDE study for its latest generation unicompartmental unloading implant, the Atlas…
– Topline data to be presented today at NACFC LEIDEN, the Netherlands (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function…
– San Diego, USA and Palma, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced successful initiation of the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan…
– Funding will be used to support go-to-market activities in Europe BARCELONA – Medical diagnostics company STAT-Diagnostica has closed an extension of its Series C financing with Siemens Venture Capital. The additional proceeds will be used to support the 2017 European launch of its…
– Acacia Pharma announces positive results from a pivotal Phase 3 trial of BAREMSIS™ for the treatment of post-operative nausea and vomiting BAREMSIS now shown to treat PONV, as well as prevent it Cambridge, UK – Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company…